Status:
COMPLETED
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
Lead Sponsor:
Allergan
Conditions:
Cervical Dystonia
Blepharospasm
Eligibility:
All Genders
18+ years
Brief Summary
This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia an...
Eligibility Criteria
Inclusion
- confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years
- treatment with Xeomin® and BOTOX® for at least 1 year each
Exclusion
- having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission
- previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm
Key Trial Info
Start Date :
January 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01814774
Start Date
January 1 2013
End Date
July 1 2013
Last Update
July 3 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Bergen, Norway
2
Wakefield, United Kingdom